Structural Characterization of SmIII(EDTMP)

Degradation of phosphonates in Co(II)/peroxymonosulfate process: Performance and mechanism

The increased release of phosphonates to natural waters causes global concern due to their potential threat to the aquatic environment. It is curial to mineralize phosphonates to orthophosphate (PO₄^3-) before they are thoroughly removed from wastewater via conventional biological treatment. In this study, we systematically investigated the performance and mechanism of degradation of phosphonates in Co(II)-triggered peroxymonosulfate (PMS) activation process. The degradation efficiency of various phosphonates is highly dependent on their coordination with Co(II). Using 1-hydroxyethane 1,1-diphosphonic acid (HEDP) as a target pollutant, the Co(II)/PMS process is effective in a broad solution pH range from 5.0 to 10.0. Multiple experimental results imply that Co(II)-PMS complex is the primary reactive species, while hydroxyl radicals (HO^•), sulfate radicals (SO₄^•-), singlet oxygen (¹O₂) and Co(III) play as the secondary reactive species for the degradation of HEDP. The presence of Cl^-, HCO₃^-, and natural organic matters (NOM) inhibits the degradation of HEDP. However, in real water samples, the selectivity and efficiency for HEDP removal in the Co(II)/PMS process are higher than that in free radicals-mediated advanced oxidation processes. This study not only sheds new lights on the mechanism of Co(II)-triggered PMS activation process, but also provides feasible technology for the degradation of phosphonates in wastewater.

Pharmaceutical and clinical development of phosphonate-based radiopharmaceuticals for the targeted treatment of bone metastases

Therapeutic phosphonate-based radiopharmaceuticals radiolabeled with beta, alpha and conversion electron emitting radioisotopes have been investigated for the targeted treatment of painful bone metastases for >35years. We performed a systematic literature search and focused on the pharmaceutical development, preclinical research and early human studies of these radiopharmaceuticals. The characteristics of an ideal bone-targeting therapeutic radiopharmaceutical are presented and compliance with these criteria by the compounds discussed is verified. The importance of both composition and preparation conditions for the stability and biodistribution of several agents is discussed. Very few studies have described the characterization of these products, although knowledge on the molecular structure is important with respect to in vivo behavior. This review discusses a total of 91 phosphonate-based therapeutic radiopharmaceuticals, of which only six agents have progressed to clinical use. Extensive clinical studies have only been described for (186)Re-HEDP, (188)Re-HEDP and (153)Sm-EDTMP. Of these, (153)Sm-EDTMP represents the only compound with worldwide marketing authorization. (177)Lu-EDTMP has recently received approval for clinical use in India. This review illustrates that a thorough understanding of the radiochemistry of these agents is required to design simple and robust preparation and quality control methods, which are needed to fully exploit the potential benefits of these theranostic radiopharmaceuticals. Extensive biodistribution and dosimetry studies are indispensable to provide the portfolios that are required for assessment before human administration is possible. Use of the existing knowledge collected in this review should guide future research efforts and may lead to the approval of new promising agents.

Harnessing the bone-seeking ability of Ca(ii)-like metal ions in the treatment of metastatic cancer and resorption disorders

In this tutorial review, we explore how a special relationship between metal ions and bones has been exploited to target therapeutic agents.